{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:13:39Z","timestamp":1754162019327,"version":"3.41.2"},"reference-count":135,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Lung cancer is the leading cause of cancer-related deaths worldwide, and stage IV lung cancer is frequently managed with targeted therapy. Renal and hepatic impairment frequently coexist with cancer, often requiring a reduction in targeted therapy dosage. This systematic review assesses the appropriateness of current targeted therapy dosage adjustments in individuals with hepatic and renal impairment by comparing package insert recommendations with available pharmacokinetic studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We reviewed the most recent guidelines from the National Comprehensive Cancer Network (NCCN) on the use of non-monoclonal antibody targeted therapy. We also examined all package inserts for information on dose adjustment in cases of hepatic and renal impairment. We then systematically searched for studies that involved pharmacokinetic analysis in populations with hepatic or renal impairment, as well as those undergoing hemodialysis and peritoneal dialysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We identified 44 studies from 21 oral lung cancer therapies that met the inclusion criteria. We developed 13 new recommendations and updated 7 existing ones regarding targeted therapy dose adjustment in cases of hepatic and renal impairment compared to the information provided in the package insert. Several drugs have not published their pharmacokinetic results in a scientific journal, which limits access to their appropriateness. Moreover, there is a lack of research on pharmacokinetic analysis of targeted therapy in patients undergoing hemodialysis and peritoneal dialysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Adjusting the dosage of targeted therapy in hepatic and renal impairment based on pharmacokinetic analysis is essential to broaden the usage, improve effectiveness, and minimize side effects. Further pharmacokinetic research on the usage in unstudied populations is strongly advised.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Prospero registration number<\/jats:title>\n<jats:p>CRD42024518123.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324056","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T17:24:31Z","timestamp":1753809871000},"page":"e0324056","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-9907","authenticated-orcid":true,"given":"Harri","family":"Hardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Fitrianti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Elliora","family":"Utama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-5277","authenticated-orcid":true,"given":"Ananda Pipphali","family":"Vidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurul Gusti","family":"Khatimah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Aristyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-8634","authenticated-orcid":true,"given":"Hana Khairina Putri","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2123-6448","authenticated-orcid":true,"given":"Vivian","family":"Soetikno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"3","key":"pone.0324056.ref001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"pone.0324056.ref002","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"DS Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0324056.ref003","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"M Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"7","key":"pone.0324056.ref004","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/1055-9965.EPI-15-0036","article-title":"Comorbidity and Survival in Lung Cancer Patients","volume":"24","author":"KMM Islam","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"pone.0324056.ref005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1385\/MO:20:1:25","article-title":"Liver metastasis at the time of initial diagnosis of lung cancer","volume":"20","author":"K Kagohashi","year":"2003","journal-title":"Med Oncol"},{"issue":"3","key":"pone.0324056.ref006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/cpt.2633","article-title":"Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis","volume":"112","author":"A-M Vasilogianni","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"pone.0324056.ref007","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00228-020-02897-x","article-title":"Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study","volume":"76","author":"JM Han","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"19","key":"pone.0324056.ref008","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.3390\/cancers14194786","article-title":"Clinical Prognosis of Lung Cancer in Patients with Moderate Chronic Kidney Disease","volume":"14","author":"T Kim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"pone.0324056.ref009","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/jgs.14809","article-title":"Inappropriate Medication in Non-Hospitalized Patients With Renal Insufficiency: A Systematic Review","volume":"65","author":"M D\u00f6rks","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"pone.0324056.ref010","doi-asserted-by":"crossref","first-page":"20503121221150104","DOI":"10.1177\/20503121221150104","article-title":"Prevalence of inappropriate drug dose adjustment and associated factors among inpatients with renal impairment in Africa: A systematic review and meta-analysis","volume":"11","author":"D Dale","year":"2023","journal-title":"SAGE Open Med"},{"issue":"4","key":"pone.0324056.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","author":"SD Krens","year":"2019","journal-title":"Lancet Oncol"},{"key":"pone.0324056.ref012","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"pone.0324056.ref013","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"AKP Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"pone.0324056.ref014","first-page":"4892","article-title":"Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors","volume":"12","author":"D Zhao","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"8","key":"pone.0324056.ref015","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"H Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"pone.0324056.ref016","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"DR Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"pone.0324056.ref017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","article-title":"Reporting a population pharmacokinetic-pharmacodynamic study: a journal\u2019s perspective","volume":"53","author":"KM Jamsen","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"pone.0324056.ref018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"MH Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"issue":"27","key":"pone.0324056.ref019","doi-asserted-by":"crossref","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"JJ Deeks","year":"2003","journal-title":"Health Technol Assess"},{"issue":"1","key":"pone.0324056.ref020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7326\/M18-1376","article-title":"PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies","volume":"170","author":"RF Wolff","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0324056.ref021","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"U Majeed","year":"2021","journal-title":"J Hematol Oncol"},{"key":"pone.0324056.ref022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"M Yuan","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"pone.0324056.ref023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"J-C Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0324056.ref024","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Afatinib","volume":"56","author":"S Wind","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"pone.0324056.ref025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-014-2403-2","article-title":"Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors","volume":"73","author":"M Freiwald","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pone.0324056.ref026","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1038\/s41598-019-54804-9","article-title":"Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer","volume":"9","author":"K Nakao","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0324056.ref027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-014-2484-y","article-title":"Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment","volume":"74","author":"D Schnell","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"pone.0324056.ref028","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13318-016-0359-9","article-title":"Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study","volume":"42","author":"S Wiebe","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"pone.0324056.ref029","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-016-3201-9","article-title":"Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis","volume":"79","author":"H Imai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0324056.ref030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ctrc.2015.09.006","article-title":"Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis","volume":"4","author":"T Yamaguchi","year":"2015","journal-title":"Cancer Treatment Communications"},{"key":"pone.0324056.ref031","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(03)70012-8","article-title":"Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)","volume":"30","author":"M Hidalgo","year":"2003","journal-title":"Semin Oncol"},{"issue":"21","key":"pone.0324056.ref032","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1200\/JCO.2007.11.6210","article-title":"Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101","volume":"25","author":"AA Miller","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0324056.ref033","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-011-1733-6","article-title":"An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function","volume":"69","author":"CL O\u2019Bryant","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"pone.0324056.ref034","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000357211","article-title":"Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels","volume":"6","author":"M Czejka","year":"2013","journal-title":"Case Rep Oncol"},{"issue":"5","key":"pone.0324056.ref035","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JTO.0b013e3181d32287","article-title":"Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis","volume":"5","author":"Y Togashi","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"pone.0324056.ref036","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40261-022-01125-x","article-title":"The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib","volume":"42","author":"J Piscitelli","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"4","key":"pone.0324056.ref037","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10637-015-0256-0","article-title":"Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib","volume":"33","author":"N Giri","year":"2015","journal-title":"Invest New Drugs"},{"issue":"5","key":"pone.0324056.ref038","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/cas.15736","article-title":"Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight","volume":"114","author":"Y Fujiwara","year":"2023","journal-title":"Cancer Sci"},{"issue":"2","key":"pone.0324056.ref039","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/jpet.118.255919","article-title":"Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment","volume":"369","author":"E Grande","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"pone.0324056.ref040","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.13223","article-title":"Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer","volume":"83","author":"K Brown","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"pone.0324056.ref041","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.613","article-title":"A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment","volume":"8","author":"K Vishwanathan","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"pone.0324056.ref042","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s10637-019-00851-y","article-title":"Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report","volume":"38","author":"A Matsunashi","year":"2020","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0324056.ref043","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000531840","article-title":"Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report","volume":"16","author":"K Tabata","year":"2023","journal-title":"Case Rep Oncol"},{"issue":"6","key":"pone.0324056.ref044","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00280-011-1611-2","article-title":"The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib","volume":"68","author":"J Horak","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pone.0324056.ref045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000375485","article-title":"Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis","volume":"8","author":"T Yamaguchi","year":"2015","journal-title":"Case Rep Oncol"},{"issue":"2","key":"pone.0324056.ref046","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/1759-7714.12263","article-title":"Pharmacokinetic analysis of gefitinib in a patient with advanced non-small cell lung cancer undergoing hemodialysis","volume":"7","author":"J Luo","year":"2016","journal-title":"Thorac Cancer"},{"issue":"3","key":"pone.0324056.ref047","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2007.06.001","article-title":"Gefitinib administration in a patient with lung cancer undergoing hemodialysis","volume":"58","author":"N Shinagawa","year":"2007","journal-title":"Lung Cancer"},{"issue":"21","key":"pone.0324056.ref048","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"AT Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0324056.ref049","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00204-023-03524-1","article-title":"Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism","volume":"97","author":"Y-N Liu","year":"2023","journal-title":"Arch Toxicol"},{"issue":"12","key":"pone.0324056.ref050","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/jcph.1286","article-title":"Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib","volume":"58","author":"PN Morcos","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"pone.0324056.ref051","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/bdd.2282","article-title":"Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment","volume":"42","author":"MM Alsmadi","year":"2021","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"pone.0324056.ref052","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/1759-7714.14357","article-title":"Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report","volume":"13","author":"JE Park","year":"2022","journal-title":"Thorac Cancer"},{"issue":"5","key":"pone.0324056.ref053","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s10637-021-01095-5","article-title":"Effect of severe renal impairment on the pharmacokinetics of brigatinib","volume":"39","author":"N Gupta","year":"2021","journal-title":"Invest New Drugs"},{"issue":"2","key":"pone.0324056.ref054","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-020-00929-4","article-title":"Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer","volume":"60","author":"N Gupta","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"pone.0324056.ref055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-023-01339-6","article-title":"Brigatinib pharmacokinetics in patients with chronic hepatic impairment","volume":"41","author":"MJ Hanley","year":"2023","journal-title":"Invest New Drugs"},{"issue":"8","key":"pone.0324056.ref056","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","article-title":"Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor","volume":"62","author":"N Gupta","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"pone.0324056.ref057","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jcph.849","article-title":"Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase","volume":"57","author":"Y Hong","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"pone.0324056.ref058","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","article-title":"Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK\u2009+\u2009advanced tumors","volume":"87","author":"FK Hurtado","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pone.0324056.ref059","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00498254.2014.941964","article-title":"Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects","volume":"45","author":"TR Johnson","year":"2015","journal-title":"Xenobiotica"},{"issue":"23","key":"pone.0324056.ref060","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1158\/1078-0432.CCR-16-0536","article-title":"Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer","volume":"22","author":"E Wang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0324056.ref061","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-018-3517-8","article-title":"Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer","volume":"81","author":"AB El-Khoueiry","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"pone.0324056.ref062","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40261-016-0490-z","article-title":"Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer","volume":"37","author":"W Tan","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"9","key":"pone.0324056.ref063","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.1621","article-title":"Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies","volume":"60","author":"D Stypinski","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"pone.0324056.ref064","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40262-021-01015-z","article-title":"Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I\/II Study","volume":"60","author":"J Chen","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"pone.0324056.ref065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13318-021-00747-4","article-title":"A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment","volume":"47","author":"S Lin","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"10","key":"pone.0324056.ref066","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial","volume":"18","author":"D Planchard","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0324056.ref067","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"J Mazieres","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"pone.0324056.ref068","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1124\/dmd.113.053785","article-title":"Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation","volume":"41","author":"DA Bershas","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"pone.0324056.ref069","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/jcph.263","article-title":"Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites","volume":"54","author":"D Ouellet","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"pone.0324056.ref070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/pcmr.12557","article-title":"Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis","volume":"30","author":"JJ Park","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"pone.0324056.ref071","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14712598.2015.1026323","article-title":"Trametinib in the treatment of melanoma","volume":"15","author":"R Thota","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"pone.0324056.ref072","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00280-016-2993-y","article-title":"Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma","volume":"77","author":"D Ouellet","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pone.0324056.ref073","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-021-02236-7","article-title":"Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction","volume":"41","author":"PJ Voon","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"pone.0324056.ref074","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","article-title":"Clinical Pharmacokinetics of Vemurafenib","volume":"56","author":"W Zhang","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"pone.0324056.ref075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"DS Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"pone.0324056.ref076","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"RC Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"pone.0324056.ref077","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/bph.15034","article-title":"OATP1A\/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation","volume":"177","author":"Y Wang","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"3","key":"pone.0324056.ref078","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10637-020-01047-5","article-title":"Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors","volume":"39","author":"G Meneses-Lorente","year":"2021","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0324056.ref079","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10637-021-01156-9","article-title":"In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)","volume":"40","author":"G Meneses-Lorente","year":"2022","journal-title":"Invest New Drugs"},{"issue":"8","key":"pone.0324056.ref080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","article-title":"Capmatinib for the treatment of non-small cell lung cancer","volume":"19","author":"JF Vansteenkiste","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"pone.0324056.ref081","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer","volume":"383","author":"J Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0324056.ref082","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","volume":"9","author":"J Mazieres","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"pone.0324056.ref083","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1124\/dmd.119.090324","article-title":"Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite","volume":"48","author":"U Glaenzel","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"pone.0324056.ref084","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bcp.14929","article-title":"Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study","volume":"88","author":"X Chen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"pone.0324056.ref085","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s10637-020-00926-1","article-title":"Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers","volume":"38","author":"A Johne","year":"2020","journal-title":"Invest New Drugs"},{"issue":"5","key":"pone.0324056.ref086","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-022-04423-5","article-title":"Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study","volume":"89","author":"W Xiong","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"pone.0324056.ref087","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"A Drilon","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"pone.0324056.ref088","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"383","author":"A Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0324056.ref089","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"JF Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"pone.0324056.ref090","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites","volume":"43","author":"S Lacy","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"pone.0324056.ref091","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/pharmaceutics13060778","article-title":"Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment","volume":"13","author":"B Gerner","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"pone.0324056.ref092","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/jcph.714","article-title":"Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib","volume":"56","author":"L Nguyen","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"pone.0324056.ref093","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/jcph.1467","article-title":"Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma","volume":"59","author":"L Nguyen","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"pone.0324056.ref094","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000905","article-title":"Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis","volume":"43","author":"S Zimmermann","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"4","key":"pone.0324056.ref095","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/pharmaceutics16040564","article-title":"Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics","volume":"16","author":"KWK Cheung","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"pone.0324056.ref096","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1517\/17425250903008525","article-title":"Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis","volume":"5","author":"K Ikemura","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10378","key":"pone.0324056.ref097","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"AJ de Langen","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"pone.0324056.ref098","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC","volume":"28","author":"EC Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"pone.0324056.ref099","article-title":"Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies","volume":"35","author":"E Calvo","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"pone.0324056.ref100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-013-0058-5","article-title":"Population pharmacokinetics\/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer","volume":"52","author":"M Fukudo","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"pone.0324056.ref101","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/FTD.0000000000000097","article-title":"Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature","volume":"37","author":"E Petit-Jean","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"2","key":"pone.0324056.ref102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cpt.2125","article-title":"Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective","volume":"110","author":"T Heimbach","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pone.0324056.ref103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/cts.13428","article-title":"Design and conduct considerations for studies in patients with hepatic impairment","volume":"16","author":"P Ravenstijn","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"1","key":"pone.0324056.ref104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcph.1702","article-title":"Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds","volume":"61","author":"M Elmeliegy","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"pone.0324056.ref105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389200043335531","article-title":"Cytochrome P450 and liver diseases","volume":"5","author":"J-P Villeneuve","year":"2004","journal-title":"Curr Drug Metab"},{"issue":"7","key":"pone.0324056.ref106","first-page":"3461","article-title":"Management of hepatotoxicity of chemotherapy and targeted agents","volume":"11","author":"TW Mudd","year":"2021","journal-title":"Am J Cancer Res"},{"key":"pone.0324056.ref107","unstructured":"FDA. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003 [cited 27 Aug 2024]. Available: https:\/\/www.fda.gov\/media\/71311\/download"},{"issue":"1","key":"pone.0324056.ref108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2125.1991.tb05613.x","article-title":"Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine","volume":"32","author":"JH Ahmed","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"pone.0324056.ref109","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ackd.2010.05.009","article-title":"Nonrenal drug clearance in CKD: Searching for the path less traveled","volume":"17","author":"JD Momper","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"pone.0324056.ref110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00280-021-04368-1","article-title":"Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase\/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants","volume":"89","author":"JE Hibma","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0324056.ref111","unstructured":"FDA. Pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labeling. 2024 [cited 27 Aug 2024]. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing"},{"issue":"8","key":"pone.0324056.ref112","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","article-title":"Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis","volume":"10","author":"TJ Velenosi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0324056.ref113","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s43440-020-00127-w","article-title":"End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s","volume":"72","author":"MT D\u00e9ri","year":"2020","journal-title":"Pharmacol Rep"},{"key":"pone.0324056.ref114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminoncol.2020.05.001","article-title":"Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review","volume":"47","author":"E Klajer","year":"2020","journal-title":"Semin Oncol"},{"issue":"4","key":"pone.0324056.ref115","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1744-9987.12537","article-title":"Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature","volume":"21","author":"K Nakai","year":"2017","journal-title":"Ther Apher Dial"},{"issue":"1","key":"pone.0324056.ref116","first-page":"86","article-title":"Appraisal of lung cancer survival in patients with end-stage renal disease","volume":"19","author":"M-S Lu","year":"2019","journal-title":"Arch Med Sci"},{"issue":"2","key":"pone.0324056.ref117","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mds344","article-title":"Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study","volume":"24","author":"N Janus","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"pone.0324056.ref118","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.21.02529","article-title":"Call to Action for Improving Oral Anticancer Agent Adherence","volume":"40","author":"LA Levit","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0324056.ref119","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"A Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0324056.ref120","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/pharmaceutics14061216","article-title":"Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study","volume":"14","author":"V Escudero-Ortiz","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"pone.0324056.ref121","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"C Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"key":"pone.0324056.ref122","doi-asserted-by":"crossref","first-page":"108256","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Q Zhao","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"5","key":"pone.0324056.ref123","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cllc.2013.03.003","article-title":"Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity","volume":"14","author":"T Takimoto","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"pone.0324056.ref124","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2023.2277758","article-title":"Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics","volume":"19","author":"A Sarah","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"pone.0324056.ref125","first-page":"153","article-title":"Pharmaceutical approval update","volume":"39","author":"MM Goldenberg","year":"2014","journal-title":"P T"},{"issue":"5","key":"pone.0324056.ref126","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cpt.2735","article-title":"Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype","volume":"113","author":"RS Gammal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pone.0324056.ref127","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12094-016-1509-x","article-title":"Targeted cancer therapy: interactions with other medicines","volume":"19","author":"D Conde-Est\u00e9vez","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"pone.0324056.ref128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.107.018192","article-title":"Effects of chronic renal failure on liver drug transporters","volume":"36","author":"J Naud","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"pone.0324056.ref129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1023\/A:1023485519485","article-title":"Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine","volume":"20","author":"R Yumoto","year":"2003","journal-title":"Pharm Res"},{"key":"pone.0324056.ref130","doi-asserted-by":"crossref","first-page":"8539","DOI":"10.2147\/CMAR.S222278","article-title":"Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study","volume":"11","author":"Y-H Fang","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"6","key":"pone.0324056.ref131","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00280-018-3581-0","article-title":"A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types","volume":"81","author":"S Lacy","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"pone.0324056.ref132","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/psp4.12406","article-title":"Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma","volume":"8","author":"JJ Wilkins","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"pone.0324056.ref133","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO-24-01534","article-title":"Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials","volume":"43","author":"J Liu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0324056.ref134","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.3289","article-title":"Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future","volume":"116","author":"K Rowland Yeo","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"pone.0324056.ref135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00228-018-2513-6","article-title":"Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review","volume":"74","author":"T Saeheng","year":"2018","journal-title":"Eur J Clin Pharmacol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T17:24:49Z","timestamp":1753809889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324056"}},"subtitle":[],"editor":[{"given":"Zheng","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":135,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324056","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}